Lyell Immunopharma (NASDAQ:LYEL) Announces Quarterly Earnings Results, Beats Expectations By $0.91 EPS

Key Points

• Lyell Immunopharma reported a quarterly loss of ($2.89) earnings per share, significantly missing the consensus estimate of ($0.19).
• Shares of Lyell Immunopharma closed at $10.57 on Tuesday, with a market capitalization of $163.41 million and a negative price-to-earnings ratio of -0.42.
• Acadian Asset Management LLC increased its stake in the company by 204.2% during the first quarter, now holding approximately 66.05% of the stock.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($2.89) EPS for the quarter, topping the consensus estimate of ($3.80) by $0.91, Zacks reports. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.

Lyell Immunopharma Price Performance

Shares of LYEL stock traded down $0.18 on Friday, hitting $10.58. 30,659 shares of the stock traded hands, compared to its average volume of 71,908. The company has a market capitalization of $203.24 million, a PE ratio of -0.44 and a beta of -0.19. Lyell Immunopharma has a 1-year low of $7.65 and a 1-year high of $32.40. The company's fifty day moving average is $10.25 and its 200 day moving average is $10.39.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LYEL. HC Wainwright reaffirmed a "neutral" rating and issued a $10.00 target price on shares of Lyell Immunopharma in a research report on Tuesday, June 24th. Wall Street Zen lowered Lyell Immunopharma from a "hold" rating to a "strong sell" rating in a research report on Saturday.

Institutional Trading of Lyell Immunopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC increased its position in Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock worth $354,000 after buying an additional 443,614 shares during the period. AQR Capital Management LLC increased its position in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock worth $94,000 after buying an additional 154,327 shares during the period. Orbimed Advisors LLC acquired a new stake in Lyell Immunopharma in the second quarter worth $457,000. Walleye Capital LLC acquired a new stake in Lyell Immunopharma in the second quarter worth $258,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Lyell Immunopharma in the second quarter worth $159,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.